MGRO — MustGrow Biologics Share Price
- CA$52.49m
- CA$46.44m
- CA$4.71m
- 71
- 16
- 15
- 26
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 9.4 | ||
Price to Tang. Book | 9.4 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 11.14 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -14.06% | ||
Return on Equity | -12.51% | ||
Operating Margin | -17.08% |
Financial Summary
Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | CA$m | n/a | n/a | 0.01 | 0.01 | 4.71 | n/a | n/a | 372.54% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
MustGrow Biologics Corp. is a Canada-based agricultural biotechnology company focused on providing science-based biological solutions for high-value crops. The Company is engaged in developing organic biocontrol, soil amendment and bio fertility products by harnessing the natural defense mechanism and organic materials of the mustard plant to sustainably protect the global food supply. It focuses on the development and commercialization of natural biological technologies and products from mustard seed for sustainable agricultural markets. The Company is providing a natural, organic technology platform with the efficacy of synthetic chemicals that has potential application in multiple global markets. Its technology pipeline includes soil amendment & bio fertility, biocontrol, and postharvest biocontrol & food preservation. The Company is pursuing the adoption and use of its technology in the soil amendment and bio fertility markets.
Directors
- Bradley Munro NEC
- Corey Giasson PRE
- Todd Lahti CFO
- Colin Bletsky COO
- David Borecky IND
- Thomas Flow IND (43)
- Matt Kowalski IND
- Brian Quigley IND (47)
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- December 2nd, 2014
- Public Since
- July 10th, 2019
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- TSX Venture Exchange
- Shares in Issue
- 51,463,575
- Address
- 1005-201 1st Ave S, Saskatoon, S7K 1J5
- Web
- https://mustgrow.ca/
- Phone
- +1 3066682652
- Auditors
- Ernst & Young LLP
Upcoming Events for MGRO
Q1 2024 MustGrow Biologics Corp Earnings Release
MustGrow Biologics Corp Annual Shareholders Meeting
MustGrow Biologics Corp Annual Shareholders Meeting
MustGrow Biologics Corp Annual Shareholders Meeting
MustGrow Biologics Corp Annual Shareholders Meeting
Q2 2024 MustGrow Biologics Corp Earnings Release
Q2 2024 MustGrow Biologics Corp Earnings Release
Similar to MGRO
Arch Biopartners
TSX Venture Exchange
biOasis Technologies
TSX Venture Exchange
Ceapro
TSX Venture Exchange
Covalon Technologies
TSX Venture Exchange
Hemostemix
TSX Venture Exchange
FAQ
As of Today at 19:15 UTC, shares in MustGrow Biologics are trading at CA$1.02. This share price information is delayed by 15 minutes.
Shares in MustGrow Biologics last closed at CA$1.02 and the price had moved by -54.35% over the past 365 days. In terms of relative price strength the MustGrow Biologics share price has underperformed the Toronto Stock Exchange 300 Composite Index by -58.21% over the past year.
There is no consensus recommendation for this security.
MustGrow Biologics does not currently pay a dividend.
MustGrow Biologics does not currently pay a dividend.
MustGrow Biologics does not currently pay a dividend.
To buy shares in MustGrow Biologics you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of CA$1.02, shares in MustGrow Biologics had a market capitalisation of CA$52.49m.
Here are the trading details for MustGrow Biologics:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: MGRO
Based on an overall assessment of its quality, value and momentum MustGrow Biologics is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MustGrow Biologics. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -21.39%.
As of the last closing price of CA$1.02, shares in MustGrow Biologics were trading -23.57% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The MustGrow Biologics PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$1.02.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
MustGrow Biologics' management team is headed by:
- Bradley Munro - NEC
- Corey Giasson - PRE
- Todd Lahti - CFO
- Colin Bletsky - COO
- David Borecky - IND
- Thomas Flow - IND
- Matt Kowalski - IND
- Brian Quigley - IND